Journal
BIOMARKERS IN MEDICINE
Volume 11, Issue 8, Pages 677-686Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2016-0379
Keywords
biomarker; cytokines; epigenetics; individualized treatment; systemic lupus erythematosus
Categories
Funding
- National Natural Science Foundation of China [81220108017, 81522038, 81602767, 81430074]
- National Natural Science Foundation of Hunan province [2017JJ3453]
- PhD Programs Foundation of Ministry of Education of China [20120162130003]
- Programs of Science-Technology Commission of Hunan province [2013F J4202]
- Natural Key Clinical Speciality Construction Project of National Health and Family Planning Commission of the People's Republic of China
Ask authors/readers for more resources
Systemic lupus erythematosus (SLE) is a complex and highly heterogeneous disease. By now, no novel drug has been approved by the US FDA in the past 50 years, except Belimumab, a monoclonal antibody to inhibit B-cell activating factor. The stagnating drug development of lupus may be due to our limited understanding of disease etiopathogenesis and the extreme heterogeneity of patient population. Thus, the individualized treatment for SLE becomes necessary. Recently, biomarkers have shown potential in individualized treatment. This review comprehensively summarizes novel potential biomarkers, discusses their current status in preclinical studies and clinical use, sensitivity to treatments and correlation with the disease activity, and provides an insight into the possibility of biomarkers in the utilization of individualized treatment for SLE.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available